CN117100786A - 改善萝卜硫素释放的营养靶向组合物及其应用 - Google Patents
改善萝卜硫素释放的营养靶向组合物及其应用 Download PDFInfo
- Publication number
- CN117100786A CN117100786A CN202311315513.7A CN202311315513A CN117100786A CN 117100786 A CN117100786 A CN 117100786A CN 202311315513 A CN202311315513 A CN 202311315513A CN 117100786 A CN117100786 A CN 117100786A
- Authority
- CN
- China
- Prior art keywords
- composition
- glucoraphanin
- sulforaphane
- component
- kudzuvine root
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- SUVMJBTUFCVSAD-UHFFFAOYSA-N sulforaphane Chemical compound CS(=O)CCCCN=C=S SUVMJBTUFCVSAD-UHFFFAOYSA-N 0.000 title claims abstract description 120
- 239000000203 mixture Substances 0.000 title claims abstract description 85
- SUVMJBTUFCVSAD-JTQLQIEISA-N 4-Methylsulfinylbutyl isothiocyanate Natural products C[S@](=O)CCCCN=C=S SUVMJBTUFCVSAD-JTQLQIEISA-N 0.000 title claims abstract description 60
- 229960005559 sulforaphane Drugs 0.000 title claims abstract description 60
- 235000015487 sulforaphane Nutrition 0.000 title claims abstract description 60
- 235000016709 nutrition Nutrition 0.000 title abstract description 16
- 230000008685 targeting Effects 0.000 title abstract description 6
- GMMLNKINDDUDCF-JRWRFYLSSA-N [(2s,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl] (1e)-5-[(r)-methylsulfinyl]-n-sulfooxypentanimidothioate Chemical compound C[S@@](=O)CCCC\C(=N/OS(O)(=O)=O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O GMMLNKINDDUDCF-JRWRFYLSSA-N 0.000 claims abstract description 69
- RUQCCAGSFPUGSZ-OBWQKADXSA-N Glucoraphanin Natural products C[S@](=O)CCCCC(=NS(=O)(=O)O)S[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O RUQCCAGSFPUGSZ-OBWQKADXSA-N 0.000 claims abstract description 68
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 claims abstract description 44
- 244000046146 Pueraria lobata Species 0.000 claims abstract description 35
- 235000010575 Pueraria lobata Nutrition 0.000 claims abstract description 35
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 claims abstract description 22
- 229930003268 Vitamin C Natural products 0.000 claims abstract description 22
- 235000019154 vitamin C Nutrition 0.000 claims abstract description 22
- 239000011718 vitamin C Substances 0.000 claims abstract description 22
- 108010058651 thioglucosidase Proteins 0.000 claims abstract description 16
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 9
- 201000010099 disease Diseases 0.000 claims abstract description 8
- 230000002265 prevention Effects 0.000 claims abstract description 7
- 238000011282 treatment Methods 0.000 claims abstract description 4
- 240000003259 Brassica oleracea var. botrytis Species 0.000 claims description 46
- 235000011299 Brassica oleracea var botrytis Nutrition 0.000 claims description 44
- 235000017647 Brassica oleracea var italica Nutrition 0.000 claims description 42
- 239000000843 powder Substances 0.000 claims description 38
- 239000000284 extract Substances 0.000 claims description 34
- 239000007864 aqueous solution Substances 0.000 claims description 17
- 238000002360 preparation method Methods 0.000 claims description 17
- 206010028980 Neoplasm Diseases 0.000 claims description 16
- 201000011510 cancer Diseases 0.000 claims description 16
- 235000011330 Armoracia rusticana Nutrition 0.000 claims description 15
- 240000003291 Armoracia rusticana Species 0.000 claims description 15
- 241000196324 Embryophyta Species 0.000 claims description 12
- 239000006286 aqueous extract Substances 0.000 claims description 12
- 238000000034 method Methods 0.000 claims description 11
- 238000006243 chemical reaction Methods 0.000 claims description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 8
- 235000011301 Brassica oleracea var capitata Nutrition 0.000 claims description 7
- 208000024827 Alzheimer disease Diseases 0.000 claims description 6
- 206010019375 Helicobacter infections Diseases 0.000 claims description 6
- 239000012675 alcoholic extract Substances 0.000 claims description 6
- 206010003805 Autism Diseases 0.000 claims description 5
- 208000020706 Autistic disease Diseases 0.000 claims description 5
- 240000007124 Brassica oleracea Species 0.000 claims description 5
- 235000003899 Brassica oleracea var acephala Nutrition 0.000 claims description 5
- 235000001169 Brassica oleracea var oleracea Nutrition 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 239000007787 solid Substances 0.000 claims description 5
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- 235000006140 Raphanus sativus var sativus Nutrition 0.000 claims description 4
- 206010012601 diabetes mellitus Diseases 0.000 claims description 4
- 238000000338 in vitro Methods 0.000 claims description 4
- 239000008176 lyophilized powder Substances 0.000 claims description 4
- 230000001737 promoting effect Effects 0.000 claims description 4
- 235000011389 fruit/vegetable juice Nutrition 0.000 claims description 3
- 208000005069 pulmonary fibrosis Diseases 0.000 claims description 3
- 239000002002 slurry Substances 0.000 claims description 3
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002156 mixing Methods 0.000 claims description 2
- 230000001502 supplementing effect Effects 0.000 claims description 2
- 244000088415 Raphanus sativus Species 0.000 claims 1
- 239000007963 capsule composition Substances 0.000 claims 1
- 239000007916 tablet composition Substances 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 abstract description 3
- 239000003826 tablet Substances 0.000 description 37
- 239000000047 product Substances 0.000 description 20
- 102100031701 Nuclear factor erythroid 2-related factor 2 Human genes 0.000 description 9
- 108090000790 Enzymes Proteins 0.000 description 8
- 102000004190 Enzymes Human genes 0.000 description 8
- 101000588302 Homo sapiens Nuclear factor erythroid 2-related factor 2 Proteins 0.000 description 8
- 239000003963 antioxidant agent Substances 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000004128 high performance liquid chromatography Methods 0.000 description 8
- 235000006708 antioxidants Nutrition 0.000 description 7
- 150000001875 compounds Chemical class 0.000 description 7
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
- 230000003078 antioxidant effect Effects 0.000 description 6
- 239000002243 precursor Substances 0.000 description 6
- QKGJFQMGPDVOQE-UHFFFAOYSA-N Sulforaphen Natural products CS(=O)C=CCCN=C=S QKGJFQMGPDVOQE-UHFFFAOYSA-N 0.000 description 5
- 230000009471 action Effects 0.000 description 5
- 230000002113 chemopreventative effect Effects 0.000 description 5
- 239000000463 material Substances 0.000 description 5
- QKGJFQMGPDVOQE-HWKANZROSA-N raphanin Chemical compound CS(=O)\C=C\CCN=C=S QKGJFQMGPDVOQE-HWKANZROSA-N 0.000 description 5
- 239000002994 raw material Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 238000001784 detoxification Methods 0.000 description 4
- 210000004051 gastric juice Anatomy 0.000 description 4
- 230000007246 mechanism Effects 0.000 description 4
- 230000001105 regulatory effect Effects 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- 241000220259 Raphanus Species 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 239000002274 desiccant Substances 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- RWSXRVCMGQZWBV-WDSKDSINSA-N glutathione Natural products OC(=O)[C@@H](N)CCC(=O)N[C@@H](CS)C(=O)NCC(O)=O RWSXRVCMGQZWBV-WDSKDSINSA-N 0.000 description 3
- 230000036541 health Effects 0.000 description 3
- 150000002540 isothiocyanates Chemical class 0.000 description 3
- 230000035764 nutrition Effects 0.000 description 3
- 230000037361 pathway Effects 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 235000004221 Brassica oleracea var gemmifera Nutrition 0.000 description 2
- 244000178937 Brassica oleracea var. capitata Species 0.000 description 2
- 244000308368 Brassica oleracea var. gemmifera Species 0.000 description 2
- 108010024636 Glutathione Proteins 0.000 description 2
- 241000699670 Mus sp. Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 241000620140 Sinularia brassica Species 0.000 description 2
- 108091023040 Transcription factor Proteins 0.000 description 2
- 102000040945 Transcription factor Human genes 0.000 description 2
- 230000004913 activation Effects 0.000 description 2
- 231100000357 carcinogen Toxicity 0.000 description 2
- 239000003183 carcinogenic agent Substances 0.000 description 2
- 210000004027 cell Anatomy 0.000 description 2
- 230000003920 cognitive function Effects 0.000 description 2
- 238000000354 decomposition reaction Methods 0.000 description 2
- 238000011161 development Methods 0.000 description 2
- 230000018109 developmental process Effects 0.000 description 2
- 229960003180 glutathione Drugs 0.000 description 2
- 239000000399 hydroalcoholic extract Substances 0.000 description 2
- 230000006872 improvement Effects 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 230000036542 oxidative stress Effects 0.000 description 2
- 238000003359 percent control normalization Methods 0.000 description 2
- 230000000291 postprandial effect Effects 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- 239000012488 sample solution Substances 0.000 description 2
- 238000007789 sealing Methods 0.000 description 2
- 239000002904 solvent Substances 0.000 description 2
- 210000002784 stomach Anatomy 0.000 description 2
- 208000024891 symptom Diseases 0.000 description 2
- 238000000825 ultraviolet detection Methods 0.000 description 2
- 230000006269 (delayed) early viral mRNA transcription Effects 0.000 description 1
- GOZMBJCYMQQACI-UHFFFAOYSA-N 6,7-dimethyl-3-[[methyl-[2-[methyl-[[1-[3-(trifluoromethyl)phenyl]indol-3-yl]methyl]amino]ethyl]amino]methyl]chromen-4-one;dihydrochloride Chemical compound Cl.Cl.C=1OC2=CC(C)=C(C)C=C2C(=O)C=1CN(C)CCN(C)CC(C1=CC=CC=C11)=CN1C1=CC=CC(C(F)(F)F)=C1 GOZMBJCYMQQACI-UHFFFAOYSA-N 0.000 description 1
- 238000010173 Alzheimer-disease mouse model Methods 0.000 description 1
- 102000013455 Amyloid beta-Peptides Human genes 0.000 description 1
- 108010090849 Amyloid beta-Peptides Proteins 0.000 description 1
- 108700032225 Antioxidant Response Elements Proteins 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- 235000011331 Brassica Nutrition 0.000 description 1
- 241000219198 Brassica Species 0.000 description 1
- 241000219193 Brassicaceae Species 0.000 description 1
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 1
- 102000016354 Glucuronosyltransferase Human genes 0.000 description 1
- 108010092364 Glucuronosyltransferase Proteins 0.000 description 1
- 108010081687 Glutamate-cysteine ligase Proteins 0.000 description 1
- 102100033398 Glutamate-cysteine ligase regulatory subunit Human genes 0.000 description 1
- 241000590002 Helicobacter pylori Species 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 239000005913 Maltodextrin Substances 0.000 description 1
- 229920002774 Maltodextrin Polymers 0.000 description 1
- 241001465754 Metazoa Species 0.000 description 1
- 108010071382 NF-E2-Related Factor 2 Proteins 0.000 description 1
- 208000036110 Neuroinflammatory disease Diseases 0.000 description 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
- 208000018737 Parkinson disease Diseases 0.000 description 1
- 206010068956 Respiratory tract inflammation Diseases 0.000 description 1
- 206010039085 Rhinitis allergic Diseases 0.000 description 1
- 101001109714 Rhizobium meliloti (strain 1021) NAD(P)H dehydrogenase (quinone) 1 Proteins 0.000 description 1
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 1
- 208000000453 Skin Neoplasms Diseases 0.000 description 1
- 208000005718 Stomach Neoplasms Diseases 0.000 description 1
- 208000007107 Stomach Ulcer Diseases 0.000 description 1
- 206010042496 Sunburn Diseases 0.000 description 1
- 102000004357 Transferases Human genes 0.000 description 1
- 108090000992 Transferases Proteins 0.000 description 1
- 208000035868 Vascular inflammations Diseases 0.000 description 1
- 230000002159 abnormal effect Effects 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000004480 active ingredient Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000010105 allergic rhinitis Diseases 0.000 description 1
- 230000000567 anti-anemic effect Effects 0.000 description 1
- 230000001093 anti-cancer Effects 0.000 description 1
- 230000000845 anti-microbial effect Effects 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 230000000975 bioactive effect Effects 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 239000001273 butane Substances 0.000 description 1
- 230000000711 cancerogenic effect Effects 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 230000001276 controlling effect Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 235000018823 dietary intake Nutrition 0.000 description 1
- 235000015872 dietary supplement Nutrition 0.000 description 1
- 208000035475 disorder Diseases 0.000 description 1
- 239000002934 diuretic Substances 0.000 description 1
- 230000001882 diuretic effect Effects 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 230000001973 epigenetic effect Effects 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000009501 film coating Methods 0.000 description 1
- 239000007888 film coating Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 238000009472 formulation Methods 0.000 description 1
- 230000006870 function Effects 0.000 description 1
- 206010017758 gastric cancer Diseases 0.000 description 1
- 201000005917 gastric ulcer Diseases 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000009229 glucose formation Effects 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 229940037467 helicobacter pylori Drugs 0.000 description 1
- 230000002440 hepatic effect Effects 0.000 description 1
- 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
- 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
- UFVKGYZPFZQRLF-UHFFFAOYSA-N hydroxypropyl methyl cellulose Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC2C(C(O)C(OC3C(C(O)C(O)C(CO)O3)O)C(CO)O2)O)C(CO)O1 UFVKGYZPFZQRLF-UHFFFAOYSA-N 0.000 description 1
- 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
- DNDNWOWHUWNBCK-NMIPTCLMSA-N indolylmethylglucosinolate Chemical class O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1S\C(=N\OS(O)(=O)=O)CC1=CNC2=CC=CC=C12 DNDNWOWHUWNBCK-NMIPTCLMSA-N 0.000 description 1
- 239000000411 inducer Substances 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 238000011835 investigation Methods 0.000 description 1
- 239000008141 laxative Substances 0.000 description 1
- 230000002475 laxative effect Effects 0.000 description 1
- 230000003859 lipid peroxidation Effects 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 208000015486 malignant pancreatic neoplasm Diseases 0.000 description 1
- 229940035034 maltodextrin Drugs 0.000 description 1
- 230000002503 metabolic effect Effects 0.000 description 1
- 239000002207 metabolite Substances 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 210000001616 monocyte Anatomy 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- OFBQJSOFQDEBGM-UHFFFAOYSA-N n-pentane Natural products CCCCC OFBQJSOFQDEBGM-UHFFFAOYSA-N 0.000 description 1
- 230000003959 neuroinflammation Effects 0.000 description 1
- 239000002547 new drug Substances 0.000 description 1
- 239000007800 oxidant agent Substances 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 239000001301 oxygen Substances 0.000 description 1
- 229910052760 oxygen Inorganic materials 0.000 description 1
- 238000004806 packaging method and process Methods 0.000 description 1
- 201000002528 pancreatic cancer Diseases 0.000 description 1
- 208000008443 pancreatic carcinoma Diseases 0.000 description 1
- 239000000825 pharmaceutical preparation Substances 0.000 description 1
- 229940127557 pharmaceutical product Drugs 0.000 description 1
- 230000003449 preventive effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 description 1
- 238000011321 prophylaxis Methods 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000008929 regeneration Effects 0.000 description 1
- 238000011069 regeneration method Methods 0.000 description 1
- 230000002441 reversible effect Effects 0.000 description 1
- 238000005070 sampling Methods 0.000 description 1
- 230000011664 signaling Effects 0.000 description 1
- 201000000849 skin cancer Diseases 0.000 description 1
- 239000000243 solution Substances 0.000 description 1
- 230000004936 stimulating effect Effects 0.000 description 1
- 201000011549 stomach cancer Diseases 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000003786 synthesis reaction Methods 0.000 description 1
- 238000009492 tablet coating Methods 0.000 description 1
- 239000002700 tablet coating Substances 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 230000017423 tissue regeneration Effects 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/31—Brassicaceae or Cruciferae (Mustard family), e.g. broccoli, cabbage or kohlrabi
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L19/00—Products from fruits or vegetables; Preparation or treatment thereof
- A23L19/10—Products from fruits or vegetables; Preparation or treatment thereof of tuberous or like starch containing root crops
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/105—Plant extracts, their artificial duplicates or their derivatives
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/15—Vitamins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
- A61K31/375—Ascorbic acid, i.e. vitamin C; Salts thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/18—Magnoliophyta (angiosperms)
- A61K36/185—Magnoliopsida (dicotyledons)
- A61K36/48—Fabaceae or Leguminosae (Pea or Legume family); Caesalpiniaceae; Mimosaceae; Papilionaceae
- A61K36/488—Pueraria (kudzu)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Mycology (AREA)
- Biomedical Technology (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Nutrition Science (AREA)
- Diabetes (AREA)
- Psychiatry (AREA)
- Botany (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Biotechnology (AREA)
- Endocrinology (AREA)
- Obesity (AREA)
- Hematology (AREA)
- Cardiology (AREA)
- Pain & Pain Management (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pulmonology (AREA)
- Oncology (AREA)
Abstract
本发明涉及一种包含萝卜硫苷、黑芥子酶、维生素C和葛根的改善释放的营养靶向组合物,所述组合物可释放更高水平的萝卜硫素。本发明还涉及所述改善释放的营养靶向组合物在制备用于预防或治疗可利用萝卜硫素预防或治疗的疾病或病症的产品中的用途。
Description
技术领域
本发明属于生物医药领域,涉及一种利用萝卜硫素预防或治疗的疾病或病症的产品的制备以及其在水溶液中提高萝卜硫素的释放的方法。
背景技术
癌症是全球人民发病和死亡的主要原因,对人类的生命和健康造成巨大威胁,给社会发展带来了沉重的经济压力。在对抗癌症的持久战中,癌症预防的概念于1976年首次提出,癌症化学预防是指为了预防、减缓或逆转癌症的发生和发展以及降低癌症的发病率和死亡率而使用天然或合成的化学物质。
精准营养,或称营养靶向,是一种癌症化学预防的重要思路。。营养靶向是以营养基因组学为理论基础提出来的目标。营养靶向的一个主要思路是利用西兰花等膳食补充剂中的有效成分(如萝卜硫苷和萝卜硫素)激活Nrf2(即NF-E2相关因子2,一种细胞调节抗氧化应激反应的转录因子)通路,促进II相酶的表达,从而起到相应的效果。基于Nrf2通路激活效应,不仅可用于癌症化学预防,还可以到对胃溃疡、幽门螺杆菌感染的治疗和预防起到作用,起到抗氧化作用,以及对糖尿病、心血管疾病、幽门螺旋杆菌感染、自闭症、精神分裂症、抑郁症、阿尔茨海默病等在内的多种疾病的治疗和预防作用。
萝卜硫素(Sulforaphane,SFN)化学名为1-异硫氰酸-4-甲磺酰基丁烷,又称莱菔硫烷,属于异硫氰酸酯类,是从西兰花中发现的一种具有预防癌症能力的生物活性物质,是迄今为止在蔬菜中发现的最强的抗癌成分。针对萝卜硫素的分子作用机理研究及细胞实验结果表明,萝卜硫素通过调控II相酶活性对I相酶代谢物或外来物激活人体抗氧化能力与代谢脱毒等相关基因的表达,起到类似于癌症化学预防的作用(Myzak MC,DashwoodRH.Cancer Lett.,2006,233:208-18.)。萝卜硫素是一种极为有效的Nrf2诱导剂,主要作用机制是激活Nrf2信号通路,调节Ⅱ相酶(NQO1、谷胱甘肽巯基转移酶、γ-谷氨酰半胱氨酸合成酶、葡萄糖醛酸基转移酶等)的活性,调控抗氧化剂反应元件等。现有技术公开了萝卜硫素及其前体化合物萝卜硫苷的多种活性和作用,例如预防结肠癌、胰腺癌和幽门螺杆菌感染而引起的胃癌等作用(CN1935003A;CN1170472C;CN101208079B),Nrf2是调节许多解毒酶和抗氧化剂酶的表达的转录因子。已知萝卜硫素和萝卜硫苷是针对革兰氏阳性细菌和革兰氏阴性细菌和酵母的抗微生物活性。一方面,对莱菔硫烷的作用机制的分子基础的调查表明萝卜硫素和萝卜硫苷通过刺激II相解毒酶间接地充当抗氧化剂,并通过小鼠模型证明其对帕金森氏病有保护作用,且具有利尿、抗贫血和通便能力。另一方面,作为莱菔硫烷类化合物的萝卜硫素和萝卜硫苷还被证实具有抗紫外线辐射的性质,由此避免晒伤、由ROS(活性氧)引起的退化和皮肤癌的发生(Talalay P.;Fahey J.W.;Healy Z.R.;Wehage S.L.;Benedict A.L.;Min C.;Dinkova-Kostova A.T.PNAS,2007,104,17500-17505;CN104284885B),其还保护机体免于遭受诸如哮喘、变应性鼻炎和慢性阻塞性肺病(COPD)的呼吸道炎症(RiedI M.A.:Saxon A.;Diaz-Sanchez D.CIinical Immunology.2009,130,244-251)。近年来已证明因子Nrf2在生长因子调控、信号传导和组织修复(具体地,由氧化应激诱导的肝再生)中具有重要作用(Beyer T.et al.The EMBO Journal,2008,27,212-223)。
总之,基于上述机制,已发现和证实作为异硫氰酸酯的萝卜硫素具有多种与其II相酶调节作用和Nrf2激活作用相关的活性和功能。随着研究的不断深入,通过动物试验和临床试验的验证,人们发现萝卜硫素除了癌症化学预防领域的作用外,还对包括糖尿病、心血管疾病、幽门螺旋杆菌感染、自闭症、精神分裂症、抑郁症、阿尔茨海默病(Alzheimerdisease,AD)等在内的多种疾病也具有预防和/或治疗的作用。例如,萝卜硫素可以减少2型糖尿病患者的肝糖产生量,降低患者体内血糖含量(Axelsson AS et al.Sci TranslMed.,2017,9(394));能够减轻小鼠血管炎症,阻止TNF-α诱导的单核细胞对原代上皮细胞的黏附(Nallasamy P et al.J Nutr Biochem.,2014,25(8):824-33.);抑制幽门螺旋杆菌在小鼠和人类的胃部定殖,减轻感染引发的胃部炎症(Yanaka A et al.Cancer Prev Res(Phila).,2009,2(4):353-60.);在临床试验中能逆转自闭症相关的异常症状,例如改善患者体内氧化应激、低抗氧化能力、受抑制的谷胱甘肽合成、减弱线粒体能力与氧化磷酸化作用和脂质过氧化和神经炎症的现象(Singh K,et al.Proc Natl Acad Sci USA,2014,111(43):15550-5.);可以有效提高精神分裂症患者的认知功能(Shiina A,et al.ClinPsychopharmacol Neurosci.,2015,13(1):62-7.);饮食摄入富含萝卜硫素的西兰花芽苗对抑郁症有预防作用(Zhang JC,et al.J Nutr Biochem.,2017,39:134-144.);给予萝卜硫素可改善β-淀粉样蛋白(amyloidβ-protein,Aβ)诱导的急性AD小鼠模型在Y迷宫和被动回避行为测试中的认知功能(Kim HV,et al.Amyloid.,2013,20(1):7-12.)。相比于其它直接抗氧化剂(其中每个分子仅能够中和另一自由基分子并且它们在该过程中被破坏),萝卜硫素的抗氧化能力更持久和有效,因为其激活牵涉针对任何氧化剂或致癌物(表观遗传因子)的保护作用的基因(Young-Joon S.Science.2003,3,768)此外,韩丽等报道了萝卜硫素通过Nrf2途径对于减轻肺纤维化的作用(韩丽,江涛,《中国新药与临床杂志》,2016第12期)。已经知道,十字花科植物是萝卜硫素及其前体化合物萝卜硫苷的主要来源。在十字花科植物中,西兰花(又名绿花菜、青花菜等,为十字花科芸苔属植物)是提供萝卜硫素及其前体化合物萝卜硫苷的主要来源。
十字花科植物中还含有其它化合物,例如吲哚芥子油苷(indoleglucosinolates),该化合物对机体的健康不利的。这些化合物不仅激活解毒系统能力较弱,而且可以生物激活某些致癌物的系统。因此,选用西兰花作为原料而尽可能避免其它不利化合物(CN1935003A)。
已知在西兰花种子和芽苗(嫩芽)中前体萝卜硫苷含量相对更高。即便如此,要想通过食用西兰花来摄入有效剂量的萝卜硫素仍是不现实的。因此,有必要通过对西兰花进行提取,通过其提取物实现其有效的生物效能。
然而,西兰花中含有的是没有生物活性的萝卜硫素前体,即萝卜硫苷,需要十字花科植物中所含的黑芥子酶分解萝卜硫苷,才能使萝卜硫苷转化成有活性的萝卜硫素。在一定的条件下,黑芥子酶可以将硫代葡萄糖苷分解,生成包括有生物活性的异硫代氰酸盐在内的产物。但是,我们发现,即使用黑芥子酶将西兰花中的萝卜硫素前体萝卜硫苷预先转化为萝卜硫素,但产品中的萝卜硫素对氧气、对热稳定性较差,易发生降解,因此也很难保存和使用。在之前的研究中,本发明人发现,如果将黑芥子酶和萝卜硫苷原料分别制成固体形式以预混合物的形式提供,则可以在保存过程中避免酶对萝卜硫苷的分解,而在加水服用或口服后可以在溶液环境中实现对萝卜硫苷的分解作用,并实现对萝卜硫素的有效吸收(参见CN110946996A)。
在我们的研究中发现,对于现有的用于癌症预防的营养靶向组合物而言,尤其是对于固体形式存在的黑芥子酶和萝卜硫苷原料(包括以西兰花和/或其提取物形式存在的原料)的混合物而言,其在水溶液中萝卜硫素转化率偏低,释放程度有限,影响了产品的利用程度。
因此,需要克服现有的营养靶向组合物中萝卜硫素转化率低的问题,尤其是包含萝卜硫苷和黑芥子酶之组合物在水溶液中释放萝卜硫素有限的问题,迫切需要提供一种在水溶液中可改善释放萝卜硫素的包含萝卜硫苷和黑芥子酶的组合物。
发明内容
本发明人在研究中意外发现:葛根可以显著改善萝卜硫苷向萝卜硫素的转化,如果向包含萝卜硫苷和黑芥子酶以及维生素C的组合物中添加葛根,则可以很好地改善组合物在水溶液中的释放情况,显著提高萝卜硫素的转化率,改善萝卜硫素的释放。
基于此发现,在本发明的第一个方面,提供了一种改善萝卜硫素释放的营养靶向组合物,包含以下组分:
(1)提供萝卜硫苷的组分1;
(2)提供黑芥子酶的组分2;
(3)维生素C;和
(4)葛根。
在本发明中,所述提供萝卜硫苷的组分1可以是能够提供萝卜硫苷化合物来源的任何物质或原料。优选地,所述提供萝卜硫苷的组分1选自十字花科植物、其提取物及其混合物。所述十字花科植物优选选自西兰花(broccoli)、花椰菜(cauliflower)、红甘蓝(redcabbage)、球芽甘蓝(Brussels sprouts)或卷心菜,特别优选西兰花。所述十字花科植物可以是植物的全部或一部分,例如全植株、其地上部分、花球、芽苗、种子或其组合。所述提供萝卜硫苷的组分1还可以是十字花科植物的提取物,例如溶剂提取物,优选水提取物、醇提取物、水醇提取物。除了十字花科植物的植物组织、提取物及其混合物以外,本发明的提供萝卜硫苷的组分1还可以包括化学合成、半化学合成、酶法合成或生物合成的萝卜硫苷。
在本发明中,所述提供黑芥子酶的组分2可以是能够提供黑芥子酶来源的任何合适的物质或原料。优选地,所述提供黑芥子酶的组分2选自十字花科植物、其提取物及其混合物。优选地,所述提供黑芥子酶的组分2选自辣根、萝卜和甘蓝。在一些优选的实施方案中,所述提供黑芥子酶的组分2选自辣根、萝卜和甘蓝的提取物;在另一些优选的实施方案中,所述提供黑芥子酶的组分2选自辣根、萝卜和甘蓝的汁液或浆液,或者所述汁液或浆液经干燥得到的粉末。
在本发明中,所述西兰花意指西兰花植物的全部或其一部分。优选地,所述西兰花选自通常意义的可食用部分;更优选地,所述西兰花选自西兰花花球、西兰花种子和西兰花芽苗,以及其组合。
在本发明中,所述西兰花提取物意指所述西兰花植物的全部或其一部分的提取物,包括但不限于所述西兰花、西兰花花球、西兰花种子和/或西兰花芽苗的提取物。在另一方面,所述提取物为利用溶剂进行提取得到的提取物,所述提取物优选为水提取物、醇提取物或水醇提取物,特别优选为水提取物。
在本发明中,所述提供萝卜硫苷的组分1优选选自西兰花花球、西兰花种子、西兰花芽苗、西兰花提取物及其混合物、以及化学合成或生物合成形式的萝卜硫苷。
本发明中的葛根是指豆科植物野葛的干燥根。在本发明的组合物中,葛根可以是葛根干燥粉末的形式,也可以是葛根提取物的形式。优选地,本发明中的葛根是葛根提取物的形式,例如水提取物、醇提取物或水-醇提取物。所述醇可选自乙醇、甲醇、丙醇、丁醇。本发明中的葛根提取物优选是干燥的提取物。
在本发明中,所述组分1、组分2、维生素C和葛根的质量比为(10-60):(1-60):(0.1-5):(0.1-5);优选(10-40):(1-40):(0.1-2):(0.1-1),更优选为(10-30):(1-10):(0.1-2):(0.1-0.5)。在一个具体的实施方案中,按萝卜硫苷计的组分1:辣根粉(组分2):维生素C:葛根粉的质量比为(1~20):(2~8):(0.1-5):(0.1~10);在另一个具体的实施方案中,按萝卜硫苷计的组分1:辣根粉(组分2):葛根粉的质量比为(1~10):(2~8):(0.1-2):(0.1~5);在另一个具体的实施方案中,按萝卜硫苷计的组分1:辣根粉(组分2):维生素C:葛根干燥提取物的质量比为(1~10):(2~8):(0.1-2):(0.1~3);在另一个具体的实施方案中,按萝卜硫苷计的组分1:辣根粉(组分2):维生素C:葛根干燥水提取物的质量比为(1~10):(2~8):(0.1-2):(0.1~3)。
在一些实施方案中,本发明的改善萝卜硫素释放的营养靶向组合物可以由以下组分组成:
(1)提供萝卜硫苷的组分1;
(2)提供黑芥子酶的组分2;
(3)维生素C;和
(4)葛根。
本发明的组合物优选为固体形式,例如,可以为粉末、颗粒、胶囊或片剂的制剂形式。更优选地,在本发明的组合物中,所述组分1、组分2和葛根均以固体形式存在。例如,所述组分1可以是提取物、芽苗或种子的粉末(包括冻干粉)形式;所述组分2可以是干燥粉末、干燥的提取物(包括冻干粉)的形式;所述葛根可以是葛根干燥粉末或干燥提取物(优选为干燥的水提取物)的形式。
在一些优选的实施方案中,本发明的组分1选自西兰花种子提取物、西兰花芽苗粉、西兰花花球冻干粉及其混合物。
在另一方面,本发明提供了本发明所述的改善萝卜硫素释放的营养靶向组合物在制备用于预防和/或治疗可利用萝卜硫素预防和/或治疗的疾病或病症的产品中的用途。所述产品可以是药品或食品。优选地,所述产品是药品。在一些优选的实施方案中,所述可利用萝卜硫素预防和/或治疗相关的疾病或病症选自癌症、糖尿病、心血管疾病、幽门螺旋杆菌感染、自闭症、精神分裂症、抑郁症、阿尔茨海默病(Alzheimer disease,AD)和肺纤维化。
在又一方面,本发明提供了一种将萝卜硫苷体外转化为萝卜硫素的方法,包括以下步骤:
1)提供如本发明所述的改善萝卜硫素释放的营养靶向组合物,
2)将所述组合物与水或含水溶液混合。
在另一方面,本发明还提供了一种向有此需要的对象补充萝卜硫素的方法,包括向所述对象施用如本发明所述的改善萝卜硫素释放的营养靶向组合物。
在另一方面,本发明还提供了一种促进萝卜硫素在水溶液中释放的方法,包括将提供萝卜硫苷的组分1、提供黑芥子酶的组分2、维生素C与葛根混合的步骤。
在又一方面,本发明还提供了葛根与维生素C之组合在制备用于促进萝卜硫素在水溶液中释放的产品中的用途。
本发明人出乎意料地发现,通过向组合物中添加葛根,可以有效地提高包含萝卜硫苷、黑芥子酶和维生素C的组合物在水中释放萝卜硫素的转化率,获得提高的萝卜硫素释放,有效地克服萝卜硫素释放程度低的问题。
附图说明:
图1是表明本发明组合物(粉剂)及对照组合物在水溶液中萝卜硫素释放情况的柱状图;
图2是表明本发明组合物(片剂)及对照组合物在水溶液中萝卜硫素释放情况的柱状图。
具体实施方式
制备实施例1:本发明组合物1-2(粉剂)和对照组合物的制备
本发明组合物1的制备:将600g西兰花种子水提物(含萝卜硫苷13.0%,来自美国Brassica Protection Products LLC,下同)、60g辣根粉、6g维生素C、15g葛根粉混合均匀,得到0.681kg组合物1,其中萝卜硫苷占11.45%。将上述组合物按每袋5g的重量分装进小袋包装中,得到对应的粉剂产品(本发明组合物1)。
本发明组合物2的制备:将600g西兰花种子水提物(含萝卜硫苷13.0%)、60g辣根粉、6g维生素C和120g葛根粉混合均匀,得到0.786kg组合物2,其中萝卜硫苷占9.92%。将上述组合物2按每袋5g的重量分装进小袋包装中,得到对应的粉剂产品(本发明组合物2)。
本发明组合物3的制备:将400g西兰花种子水提物(含萝卜硫苷13.0%,来自美国Brassica Protection Products LLC,下同)、60g辣根粉、6g维生素C和15g葛根提取物(干燥的水提取物)混合均匀,得到0.481kg组合物3,其中萝卜硫苷占10.81%。将上述组合物按每袋5g的重量分装进小袋包装中,得到对应的粉剂产品(本发明组合物3)。
对照组合物的制备:将600g西兰花种子水提物(含萝卜硫苷13.0%)、60g辣根粉、6g维生素C和15g淀粉混合均匀,得到0.681kg对照组合物,其中萝卜硫苷占11.45%。将上述对照组合物按每袋5g的重量分装进小袋包装中,得到对应的粉剂产品(对照组合物)。
实施例2:粉剂体外释放曲线的测定:
将上述4种粉剂产品各取1g,溶解在37℃的30ml人工胃液中(按《中国药典》2015版配制并调节pH至3.5,用于模拟餐后胃液条件)进行反应,在第30min时取样通过HPLC测定水溶液中萝卜硫素的含量,并计算萝卜硫素的生成率。
萝卜硫素的HPLC测定方法:取样品溶液,过0.45μm滤膜,进行HPLC分析。HPLC条件:色谱柱:华普公司Unitary C18(4.6mm×250mm,5μm);柱温:30℃;流动相:70%水-30%乙腈;流速:0.8mL/min;进样量:10μL;紫外检测波长:245nm。
实验结果见下表1。
表1.本发明组合物1-3和对照组合物粉剂产品的萝卜硫素释放情况比较
粉剂组别 | 30min萝卜硫素生成率(%) |
本发明组合物1 | 74.1% |
本发明组合物2 | 78.4% |
本发明组合物3 | 75.9% |
对照组合物 | 24.8% |
从实验结果可见,相比于不含葛根的对照组合物而言,含葛根的本发明组合物1-3在水溶液中具有提高的萝卜硫素释放特性,萝卜硫素转化率显著提高,均提高2倍以上。这样的结果是出乎意料的。
制备实施例2:本发明组合物(片剂)及其对照片剂的制备
(1)本发明组合物(片剂1)的制备:将600g西兰花芽苗水提物(含萝卜硫苷13.0%)、150g辣根粉、12g维生素C、15g葛根粉及750g其他压片辅料(具体组成为淀粉、麦芽糊精、羟丙甲基纤维素,比例(w/w)为5:80:2,下同)混合均匀,按1g/片的片重压片,包薄膜衣,得到约1.527kg本发明片剂,其中萝卜硫苷占5.11%。将上述本发明片剂按每瓶60片分装进瓶中并加干燥剂后密封瓶口,得到对应的片剂产品。
(2)本发明组合物(片剂2)的制备:将600g西兰花芽苗水提物(含萝卜硫苷13.0%)、150g辣根粉、12g维生素C、15g葛根提取物(干燥水提取物)及750g其他压片辅料混合均匀,按1g/片的片重压片,包薄膜衣,得到约1.527kg片剂2,其中萝卜硫苷占5.11%。将上述片剂2按每瓶60片分装进瓶中并加干燥剂后密封瓶口,得到对应的片剂产品。
(3)对照片剂的制备:将600g西兰花芽苗水提物(含萝卜硫苷13.0%)、150g辣根粉、12g维生素C、15g淀粉及750g其他压片辅料混合均匀,按1g/片的片重压片,包薄膜衣,得到约1.527kg对照片剂,其中萝卜硫苷占5.11%。将上述对照片剂按每瓶60片分装进瓶中并加干燥剂后密封瓶口,得到对应的片剂产品。
实施例3:片剂体外释放曲线的测定:
将制备实施例2中制得的4种片剂产品各取2g,溶解在37℃的30ml人工胃液中(按《中国药典》2015版配制并调节pH至3.5,用于模拟餐后胃液条件)进行反应,分别在第30min时取样通过HPLC测定水溶液中萝卜硫素的含量,并计算萝卜硫素的生成率。
萝卜硫素的HPLC测定方法:取上述样品溶液,过0.45μm滤膜,进行HPLC分析。HPLC条件:色谱柱:华普公司Unitary C18(4.6mm×250mm,5μm);柱温:30℃;流动相:70%水-30%乙腈;流速:0.8mL/min;进样量:10μL;紫外检测波长:245nm。
实验结果见下表2。
表2.本发明组合物片剂1-2和对照片剂的萝卜硫素释放情况比较
片剂组别 | 30min萝卜硫素生成率(%) |
本发明片剂1 | 71.2% |
本发明片剂2 | 71.9% |
对照片剂 | 23.9% |
从实验结果可见,相比于不含葛根的对照片剂而言,含葛根的本发明片剂在水溶液中具有明显提高的萝卜硫素释放特性,萝卜硫素转化率显著提高,均提高2倍以上,这样的结果是出乎意料的。
应理解,虽然通过优选实施方案具体地公开了本发明,但是本领域技术人员可以采用本文所公开的内容所体现的本发明的任选特征、修改、改进和变化,认为这些修改、改进和变化在本发明的范围内。本文所提供的作为示例性优选实例方案的材料、方法和实施例是示例性的,并且不旨在限制本发明的范围。
Claims (17)
1.一种组合物,包含以下组分:
1)提供萝卜硫苷的组分1;
2)提供黑芥子酶的组分2;
3)维生素C;和
4)葛根。
2.如权利要求1所述的组合物,其中所述葛根选自葛根粉末和葛根提取物;
优选地,所述葛根提取物选自水提取物、醇提取物和水-醇提取物。
3.如权利要求1或2所述的组合物,其中所述组分1选自十字花科植物、其提取物及其混合物。
4.如权利要求3所述的组合物,其中所述十字花科植物为西兰花。
5.如权利要求3或4所述的组合物,其中所述十字花科植物选自植物的植株全部、一部分及其混合物。
6.如权利要求3至5中任一项所述的组合物,其中所述十字花科植物选自植物的花球、种子、芽苗及其混合物。
7.如权利要求1至5中任一项所述的组合物,其中所述组分1、所述组分2、维生素C和葛根的质量比为(10-60):(1-60):(0.1-2):(0.1-5)。
8.如权利要求1至7中任一项所述的组合物,其为固体形式。
9.如权利要求1至8中任一项所述的组合物,其为粉末、颗粒、胶囊或片剂的制剂形式。
10.如权利要求1至9中任一项所述的组合物,其中所述组分1选自西兰花种子提取物、西兰花芽苗粉、西兰花花球冻干粉及其混合物、以及化学合成或生物合成形式的萝卜硫苷。
11.如权利要求1至10中任一项所述的组合物,其中所述组分2选自辣根、萝卜、甘蓝;其汁液或浆液;以及其提取物。
12.如权利要求1至11中任一项所述的组合物在制备用于预防或治疗可利用萝卜硫素预防或治疗的疾病或病症的产品中的用途。
13.如权利要求12所述的用途,其中所述可利用萝卜硫素预防或治疗的疾病或病症选自癌症、糖尿病、心血管疾病、幽门螺旋杆菌感染、自闭症、精神分裂症、抑郁症、阿尔茨海默病和肺纤维化。
14.一种将萝卜硫苷体外转化为萝卜硫素的方法,包括以下步骤:
1)提供如权利要求1至13中任一项所述的组合物,
2)将所述组合物与水或含水溶液混合。
15.一种向有此需要的对象补充萝卜硫素的方法,包括向所述对象施用如权利要求1至13中任一项所述的组合物。
16.一种促进萝卜硫素在水溶液中释放的方法,包括将提供萝卜硫苷的组分1、提供黑芥子酶的组分2、维生素C与葛根混合的步骤。
17.葛根和维生素C之组合在制备用于促进萝卜硫素在水溶液中释放的产品中的应用。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311315513.7A CN117100786A (zh) | 2023-10-11 | 2023-10-11 | 改善萝卜硫素释放的营养靶向组合物及其应用 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202311315513.7A CN117100786A (zh) | 2023-10-11 | 2023-10-11 | 改善萝卜硫素释放的营养靶向组合物及其应用 |
Publications (1)
Publication Number | Publication Date |
---|---|
CN117100786A true CN117100786A (zh) | 2023-11-24 |
Family
ID=88802507
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202311315513.7A Pending CN117100786A (zh) | 2023-10-11 | 2023-10-11 | 改善萝卜硫素释放的营养靶向组合物及其应用 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN117100786A (zh) |
Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115813970A (zh) * | 2022-11-25 | 2023-03-21 | 深圳福山生物科技有限公司 | 一种稳定释放的营养靶向组合物及其用途 |
-
2023
- 2023-10-11 CN CN202311315513.7A patent/CN117100786A/zh active Pending
Patent Citations (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115813970A (zh) * | 2022-11-25 | 2023-03-21 | 深圳福山生物科技有限公司 | 一种稳定释放的营养靶向组合物及其用途 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP7379533B2 (ja) | グルコラファニンを含有する組成物及びその使用 | |
CA2877393C (en) | Compositions comprising sulforaphane or a sulforaphane precursor and ursolic acid | |
Epperly et al. | Antioxidant-chemoprevention diet ameliorates late effects of total-body irradiation and supplements radioprotection by MnSOD-plasmid liposome administration | |
TWI666021B (zh) | 含有寡果糖與槲皮素配醣體之組成物 | |
CN115813970B (zh) | 一种稳定释放的营养靶向组合物及其用途 | |
EP0925068B1 (en) | Use of a pharmaceutical composition containing polyphenols from grapes or from wine, in particular resveratrol, and yeast extracts | |
US20180133194A1 (en) | Method of treating inflammation using natural compounds and/or diet | |
Okwu et al. | Evaluation of the phytochemical composition of mango (Mangifera indica Linn) stem bark and leaves | |
Selvakumarasamy et al. | Costus pictus–transition from a medicinal plant to functional food: A review | |
CA2839972C (en) | Compositions containing broccoli seeds extract for treating or preventing prostate cancer | |
Younes et al. | Sweet bell pepper: A focus on its nutritional qualities and illness-alleviated properties | |
Nabavi et al. | Antihypoxic, nephroprotective and antioxidant properties of hydro-alcoholic extract of loquat flowers | |
CN117100786A (zh) | 改善萝卜硫素释放的营养靶向组合物及其应用 | |
US11571438B1 (en) | Nutraceutical compositions to up-regulate SIRT1 and methods of use | |
CN117205247A (zh) | 改善萝卜硫素释放的精准营养组合物及其用途 | |
EP3666269A1 (en) | Blood flow improver | |
ABD RAHIM et al. | Antidiabetic activity of aqueous extract of Leptospermum flavescens in alloxan induced diabetic rats | |
US20080254110A1 (en) | Composition For Enhancing Immunity and Reducing Inflammation Related to Infections | |
KR20200107809A (ko) | 자일리톨 및/또는 효소처리 스테비아로 피복된 복합비타민 과립제 | |
CN111936129A (zh) | 用于调节肾和排泄系统的天然组合产品和方法 | |
Abbasi et al. | Bioactive Compounds and Biological Activities of Allium sativum L. | |
Sharma et al. | Piperine: A review on different formulations and pharmacological activities. | |
WO2003086436A1 (fr) | Inhibiteurs d'absorption enterique de graisses contenant des extraits de plantes, et produits alimentaires contenant lesdits extraits | |
ルヒールヒーア タスキン | The effects of sulforaphane on inflammation and oxidative stress and the mechanisms | |
WO2016037971A1 (en) | Compositions comprising glucosinolates precursors of sulforaphane in combination with extracts of rosemary |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination |